Genmab Surges 15% in a Week as Shorts Back Off Before November Results

Genmab gained 15.2% over the past week, closing at DKK 2,997, a move that dwarfs the median 3.0% advance posted by its closest peers over the same period. The rally comes eight days before the company's next earnings release on November 5, and it is reshaping the positioning picture in ways worth examining.

The clearest read from the lending market is that short sellers have retreated, not advanced, into this strength. Availability is extraordinarily loose at nearly 4,900% of shares already borrowed, meaning for every share currently out on loan there are roughly 49 more available. That is well above the 52-week low of around 2,196%, itself a relaxed level. Cost to borrow has dropped by a third over the past week to just 0.71%, after briefly touching nearly 2% in mid-October. Short interest at roughly 1.1% of free float is negligible. None of that signals a crowded short side. The short score has also eased, falling from 36.6 to 33.8 in the past two sessions, moving away from rather than toward bearish territory.

The Street leans constructive. The analyst consensus is a buy, with three outperform ratings against one hold, and the mean price target of DKK 3,192 implies roughly 6.5% further from the current price. No analyst changes are recorded in the past fortnight. On valuation, the stock's P/E multiple has expanded by around 4 points over the past month, now at 26.7x, and price-to-book has risen by roughly 0.7x over the same period to 3.8x. Both moves reflect the pace of the share price recovery rather than an earnings estimate revision. EPS momentum is a notable positive: Genmab ranks in the 92nd percentile on 30-day EPS momentum and the 88th on 90-day, suggesting forward estimates have been rising. The earnings yield factor score of 82 also supports the idea that, at current prices, the stock is not obviously expensive relative to its profitability.

Institutional ownership is substantial and broadly stable. Darwin Global Management reported a position of 6.1% of shares as of late September, a large addition relative to its prior filing. BlackRock and Orbis each hold approximately 7%, with BlackRock adding modestly in the most recent period. The combined weight of the top five holders is close to 30% of shares outstanding, which compresses the effective free float and can amplify price moves when sentiment shifts. There is nothing in the insider data to flag: the most recent open-market activity was a small board-member sale in late May, and the April grants were routine compensation.

The earnings history offers a reference point without a strong pattern. The last release, on October 7, produced a one-day decline of just over 5%, which was almost entirely recovered within five trading days. The August 2026 report went the other way, with the stock gaining 5.7% on the day and extending that to 7% over the following week. The two-event sample is too small to draw a directional conclusion, but it does confirm that Genmab moves meaningfully on results day in either direction.

The specific thing to watch is the November 5 earnings release. With the stock having already recovered more than 30% over the past month and the P/E re-rating well underway, the debate will turn to whether the underlying figures justify the re-rated multiple, and whether any pipeline update on its antibody programmes changes the forward estimate trajectory.